Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2...
21 Giugno 2021 - 1:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced a Product Theater
presentation at the upcoming 81st Scientific Sessions of the annual
2021 American Diabetes Association meeting taking place virtually
June 25-29. The Product Theater will include an overview of
Diabetic Cardiomyopathy (DbCM), the increased risk of progression
to overt heart failure and death due to the disease, new data on
the wide prevalence of the disease among patients with diabetes,
the role of aldose reductase in the pathogenesis of disease, and a
review of the ongoing ARISE-HF global registrational trial of
AT-001, a novel and selective aldose reductase inhibitor.
Presentation Details
- Product Theater:
“Diabetic Cardiomyopathy – An Opportunity for Clinical
Intervention” presented by Jim Januzzi, MD, Hutter Family
Professor of Medicine at Harvard Medical School, and Riccardo
Perfetti, MD, PhD, Chief Medical Officer of Applied
Therapeutics.
- The Product Theater presentation
will be available virtually on the 2021 American Diabetes
Association Annual Meeting website, and available after the meeting
on the Events page under the Investor Relations section of the
Applied Therapeutics website.
“We are pleased to share this new data with the
medical community, which confirms the high prevalence of DbCM,”
said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied
Therapeutics. “It is very important for physicians to be aware of
the risk factors for developing DbCM and to monitor the disease,
especially as progression to overt heart failure and death is
1.5-fold higher in patients with DbCM compared to Diabetic patients
without DbCM,” said Jim Januzzi, MD, Hutter Family Professor of
Medicine at Harvard Medical School.
About Applied
TherapeuticsApplied Therapeutics is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need. The Company’s lead drug candidate, AT-007,
is a novel central nervous system penetrant Aldose Reductase
Inhibitor (ARI) for the treatment of CNS rare metabolic diseases,
including Galactosemia, SORD Deficiency and PMM2-CDG. The Company
is also developing AT-001, a novel potent ARI, for the treatment of
Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of Diabetic retinopathy, as well as novel dual PI3k
inhibitors in preclinical development for orphan oncology
indications.
To learn more, please visit
www.appliedtherapeutics.com and follow the company on Twitter
@Applied_Tx.
Investors:Maeve
Conneighton(212) 600-1902
orappliedtherapeutics@argotpartners.com
Media:media@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Ott 2023 a Ott 2024